Download presentation
Presentation is loading. Please wait.
Published byMargaretMargaret Gibbs Modified over 9 years ago
1
UBC-Case 1 Samuel Yip PhD, MD, FRCPC Western Stroke Day 2012
2
History 30 year old RH female Recently from UK While pushing herself off a table, sudden onset of left hemiplegia and decrease LOC 6 months ago she had1 spell of sudden onset of dizziness No neck pain and no neck trauma No SOB and no leg pain
3
History No other stroke risk factors Non-smoker No Family history of stroke OCP (12 yrs) for Endometriosis
4
Examination Initial Examination: –AVSS –Mild decrease in left nasolabial fold –Left deltoid weakness of 4+; no drift –NIHSS = 1
9
Too Good to Treat StudyYearMedian NIHSS NPoor Outcome Barber et al., 20011996-19993-mild; 6-RI9832.7% (NHD) Nedeltchev et al., 20072000-20062 (1 to 14)16223.5% (mRS 2 to 5) Smith et al., 200520024132.7% (NHD) Smith et al., 20112003-20092 (1 to 5)2920028.3% (NHD) van den Berg et al., 200920052711.1% (mRS 2 to 3) Willey et al, 20112004-20081(0 to 19)12710.2%(NHD) NHD = No Home Discharge
10
TREATMENT OPTIONS Iv-tPA Heparin ASA +/- Plavix ASA +/- Plavix + Heparin Enroll into a RCT – TEMPO-1
13
Fluids, ASA, Heparin sc BASELINE CTA 24 hr CTA
15
Case Cont: Investigations TTE and TEE showed –Large PFO –Spontaneous Right to Left shunt Hypercoagulable workup was negative Pelvic and Leg U/S showed no DVTs
16
Giant Hepatic Hemangiomas
17
Diagnosis ? Paradoxical Embolism –Hepatic Hemangioma – Large venous lakes with potential stasis 2 case reports suggesting hemangioma causing pulmonary embolism –Recent travel –Valsalva maneuver –Large spontaneous right left shunt
18
Secondary Prevention Stop OCP ASA 81 mg once a day Coumadin Coumadin then PFO Closure
19
PFO and Stroke: Atrial septum – overlapping of the septum primum and septum secundum. When the fusion of these 2 structures fails, then a patent foramen is formed. This act as conduit for R to L shunt in adult life.
20
PFO and Cryptogenic Stroke 25% of general population have a PFO ~ 40% of young cryptogenic stroke patients have a PFO Overall et al., 2000
21
PFO and Stroke: Pathophysiology Paradoxical Embolism
22
LA RA AO IAS T Srivastava etl., NEJM 1997
23
PFO and Stroke: Pathophysiology Paradoxical Embolism Atrial Vulnerability – Paroxysmal Atrial Fibrillation Endothelial dysfunction
24
PFO and cryptogenic stroke: Natural History Risk of recurrent stroke is low – ~ 0.5 to 1% per year. (From recent cohort study and placebo randomized control trials ).
25
PFO in Cryptogenic Stroke Study (PICSS) Substudy of WARSS (Multicenter, randomized, DB study, ASA (325 mg) vs Warfarin (mean INR 2.1); n = 2206) –Excluded symptomatic carotid and cardioembolic stroke 630 patients underwent TEE –42% had a cryptogenic stroke –39% of the cryptogenic stroke had a PFO Primary end point: recurrent ischemic stroke or death in 2 years Homma et al., Circulation, 2002
26
PICSS Results Homma et al., Circulation, 2002
27
PFO Closure Devices for Cryptogenic Stroke StudyDevice MedicalRisk Ratio (95% CI) CLOSURE 1STARFlex Septal Closure System 12/44713/4620.90 (0.41,1.98) RESPECTAmplatzer PFO Occluder 9/49916/4810.49 (0.21,1.11) PCAmplatzer PFO Occluder 1/2045/2100.20 (0.02,1.72) CLOSURE – Fulran et al., NEJM 2012 RESPECT – Carroll et al., TCT 2012 PC - Meier, et al., TCT 2012
28
PFO Closure in Cryptogenic Stroke: Conclusion There is no evidence for routine PFO closure in patients with cryptogenic stroke. We should continue to enroll patients in RCT trials to evaluate the effectiveness of endovascular PFO closure as a secondary stroke prevention strategy.
29
PFO CLOSURE
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.